Changes in antipsychotics and other psychotropic drugs during a 30-month lifestyle intervention among outpatients with schizophrenia

Mikkel Højlund, Anja Friis Elliott, Nikolaj Juul Madsen, Anne Grethe Viuff, Povl Munk-Jørgensen, Peter Hjorth

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

104 Downloads (Pure)

Resumé

BACKGROUND: Patients with schizophrenia have high risk of early death from diabetes and cardiovascular diseases, partly because of poor lifestyle and partly because of long-lasting exposure to antipsychotic treatment.

AIMS: To investigate the influence of a lifestyle intervention program on changes in psychotropic medication in a non-selected cohort of patients with schizophrenia.

METHODS: Observational study of outpatients in the Central Denmark Region during a 30-month lifestyle program.

RESULTS: One hundred and thirty-six patients were enrolled and 130 were available for analysis. Median follow-up time was 15.9 months (range 1-31 months). Nineteen patients (15%) were not treated with antipsychotic drugs during the study period. 54% of the 111 patients exposed to antipsychotics were subject to monotherapy at index and at follow-up. The median defined daily dose (DDD) of antipsychotics was 1.33 at index (interquartile range (IQR) 0.67-2.00) and 1.07 at follow-up (IQR 0.40-1.50). 52% of the patients experienced a decrease in DDD during the study period (median change 0.33; IQR 1.00-0.43). There were no significant differences between the patients with decreased, stable or increased DDD with regard to age, sex, follow-up time and time since diagnosis. The number of prescriptions was significantly higher in the patients who decreased their DDD and the proportion of antipsychotic depot formulation was higher in those who increased their DDD.

CONCLUSIONS: Most patients decreased or stabilized their total dose of antipsychotic medication during the study period. Many patients were subject to antipsychotic polypharmacy. The extent of participation in the lifestyle intervention program did not correlate with the changes in dosing of antipsychotic medication.

OriginalsprogEngelsk
TidsskriftNordic Journal of Psychiatry
Vol/bind71
Udgave nummer8
Sider (fra-til)598-604
ISSN0803-9488
DOI
StatusUdgivet - 2017

Fingeraftryk

Psychotropic Drugs
Outpatients
Denmark
Prescriptions

Citer dette

Højlund, Mikkel ; Elliott, Anja Friis ; Madsen, Nikolaj Juul ; Viuff, Anne Grethe ; Munk-Jørgensen, Povl ; Hjorth, Peter. / Changes in antipsychotics and other psychotropic drugs during a 30-month lifestyle intervention among outpatients with schizophrenia. I: Nordic Journal of Psychiatry. 2017 ; Bind 71, Nr. 8. s. 598-604 .
@article{548bd393971e40a7a1928c330bc7540b,
title = "Changes in antipsychotics and other psychotropic drugs during a 30-month lifestyle intervention among outpatients with schizophrenia",
abstract = "BACKGROUND: Patients with schizophrenia have high risk of early death from diabetes and cardiovascular diseases, partly because of poor lifestyle and partly because of long-lasting exposure to antipsychotic treatment.AIMS: To investigate the influence of a lifestyle intervention program on changes in psychotropic medication in a non-selected cohort of patients with schizophrenia.METHODS: Observational study of outpatients in the Central Denmark Region during a 30-month lifestyle program.RESULTS: One hundred and thirty-six patients were enrolled and 130 were available for analysis. Median follow-up time was 15.9 months (range 1-31 months). Nineteen patients (15{\%}) were not treated with antipsychotic drugs during the study period. 54{\%} of the 111 patients exposed to antipsychotics were subject to monotherapy at index and at follow-up. The median defined daily dose (DDD) of antipsychotics was 1.33 at index (interquartile range (IQR) 0.67-2.00) and 1.07 at follow-up (IQR 0.40-1.50). 52{\%} of the patients experienced a decrease in DDD during the study period (median change 0.33; IQR 1.00-0.43). There were no significant differences between the patients with decreased, stable or increased DDD with regard to age, sex, follow-up time and time since diagnosis. The number of prescriptions was significantly higher in the patients who decreased their DDD and the proportion of antipsychotic depot formulation was higher in those who increased their DDD.CONCLUSIONS: Most patients decreased or stabilized their total dose of antipsychotic medication during the study period. Many patients were subject to antipsychotic polypharmacy. The extent of participation in the lifestyle intervention program did not correlate with the changes in dosing of antipsychotic medication.",
keywords = "Journal Article",
author = "Mikkel H{\o}jlund and Elliott, {Anja Friis} and Madsen, {Nikolaj Juul} and Viuff, {Anne Grethe} and Povl Munk-J{\o}rgensen and Peter Hjorth",
year = "2017",
doi = "10.1080/08039488.2017.1365379",
language = "English",
volume = "71",
pages = "598--604",
journal = "Nordic Journal of Psychiatry",
issn = "0803-9488",
publisher = "Taylor & Francis",
number = "8",

}

Changes in antipsychotics and other psychotropic drugs during a 30-month lifestyle intervention among outpatients with schizophrenia. / Højlund, Mikkel; Elliott, Anja Friis; Madsen, Nikolaj Juul; Viuff, Anne Grethe; Munk-Jørgensen, Povl; Hjorth, Peter.

I: Nordic Journal of Psychiatry, Bind 71, Nr. 8, 2017, s. 598-604 .

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Changes in antipsychotics and other psychotropic drugs during a 30-month lifestyle intervention among outpatients with schizophrenia

AU - Højlund, Mikkel

AU - Elliott, Anja Friis

AU - Madsen, Nikolaj Juul

AU - Viuff, Anne Grethe

AU - Munk-Jørgensen, Povl

AU - Hjorth, Peter

PY - 2017

Y1 - 2017

N2 - BACKGROUND: Patients with schizophrenia have high risk of early death from diabetes and cardiovascular diseases, partly because of poor lifestyle and partly because of long-lasting exposure to antipsychotic treatment.AIMS: To investigate the influence of a lifestyle intervention program on changes in psychotropic medication in a non-selected cohort of patients with schizophrenia.METHODS: Observational study of outpatients in the Central Denmark Region during a 30-month lifestyle program.RESULTS: One hundred and thirty-six patients were enrolled and 130 were available for analysis. Median follow-up time was 15.9 months (range 1-31 months). Nineteen patients (15%) were not treated with antipsychotic drugs during the study period. 54% of the 111 patients exposed to antipsychotics were subject to monotherapy at index and at follow-up. The median defined daily dose (DDD) of antipsychotics was 1.33 at index (interquartile range (IQR) 0.67-2.00) and 1.07 at follow-up (IQR 0.40-1.50). 52% of the patients experienced a decrease in DDD during the study period (median change 0.33; IQR 1.00-0.43). There were no significant differences between the patients with decreased, stable or increased DDD with regard to age, sex, follow-up time and time since diagnosis. The number of prescriptions was significantly higher in the patients who decreased their DDD and the proportion of antipsychotic depot formulation was higher in those who increased their DDD.CONCLUSIONS: Most patients decreased or stabilized their total dose of antipsychotic medication during the study period. Many patients were subject to antipsychotic polypharmacy. The extent of participation in the lifestyle intervention program did not correlate with the changes in dosing of antipsychotic medication.

AB - BACKGROUND: Patients with schizophrenia have high risk of early death from diabetes and cardiovascular diseases, partly because of poor lifestyle and partly because of long-lasting exposure to antipsychotic treatment.AIMS: To investigate the influence of a lifestyle intervention program on changes in psychotropic medication in a non-selected cohort of patients with schizophrenia.METHODS: Observational study of outpatients in the Central Denmark Region during a 30-month lifestyle program.RESULTS: One hundred and thirty-six patients were enrolled and 130 were available for analysis. Median follow-up time was 15.9 months (range 1-31 months). Nineteen patients (15%) were not treated with antipsychotic drugs during the study period. 54% of the 111 patients exposed to antipsychotics were subject to monotherapy at index and at follow-up. The median defined daily dose (DDD) of antipsychotics was 1.33 at index (interquartile range (IQR) 0.67-2.00) and 1.07 at follow-up (IQR 0.40-1.50). 52% of the patients experienced a decrease in DDD during the study period (median change 0.33; IQR 1.00-0.43). There were no significant differences between the patients with decreased, stable or increased DDD with regard to age, sex, follow-up time and time since diagnosis. The number of prescriptions was significantly higher in the patients who decreased their DDD and the proportion of antipsychotic depot formulation was higher in those who increased their DDD.CONCLUSIONS: Most patients decreased or stabilized their total dose of antipsychotic medication during the study period. Many patients were subject to antipsychotic polypharmacy. The extent of participation in the lifestyle intervention program did not correlate with the changes in dosing of antipsychotic medication.

KW - Journal Article

U2 - 10.1080/08039488.2017.1365379

DO - 10.1080/08039488.2017.1365379

M3 - Journal article

C2 - 28836471

VL - 71

SP - 598

EP - 604

JO - Nordic Journal of Psychiatry

JF - Nordic Journal of Psychiatry

SN - 0803-9488

IS - 8

ER -